Analysts’ Recent Ratings Changes for Revolution Medicines (RVMD)

Several analysts have recently updated their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 8/11/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $210.00 to $231.00. They now have a “buy” rating on the stock.
• 8/10/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Wolfe Research. They now have a $220.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc. They now have a $230.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Wedbush from $192.10 to $201.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $230.00 price target on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $182.00 to $203.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Guggenheim from $235.00 to $240.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $236.00 to $240.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Revolution Medicines had its price target raised by Wedbush from $181.00 to $192.10. They now have an “outperform” rating on the stock.
• 7/20/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $235.00 to $236.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Revolution Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/9/2026 – Revolution Medicines had its price target raised by Guggenheim from $205.00 to $235.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Revolution Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $195.00 price target on the stock.
• 7/6/2026 – Revolution Medicines had its price target raised by Mizuho from $185.00 to $215.00. They now have an “outperform” rating on the stock.
• 7/2/2026 – Revolution Medicines had its price target raised by Wedbush from $165.00 to $181.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $179.00 to $210.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $183.00 to $235.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, insider Mark A. Goldsmith sold 10,020 shares of Revolution Medicines stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $1,564,322.40. Following the transaction, the insider owned 267,330 shares in the company, valued at approximately $41,735,559.60. The trade was a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 60,400 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the sale, the chief operating officer directly owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This trade represents a 27.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 132,497 shares of company stock worth $21,470,486. 7.60% of the stock is owned by company insiders.

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.